Triamcinolone
- TRADE NAMES: Aristocort; Aristospan (Sabex); Azmacort (Kos); Kenacort; Kenalog (Apothecon); Nasacort (Aventis); Triacet (Teva)
- INDICATIONS: Arthralgias, asthma, dermatoses, inflammatory ocular conditions, rhinitis
- CLASS: Corticosteroid / Glucocorticoid, Corticosteroid, systemic, Corticosteroid, topical
- HALF-LIFE: 17–25 days
ACE inhibitors, Acetazolamide, Adrenergic neurone blockers, Aldesleukin, Alpha blockers, Aminoglutethimide, Aminophylline, Amphotericin B, Angiotensin II receptor antagonists, Antacids, Antidiabetics, Antifungals, Aprepitant, Aspirin, Barbiturates, Beta blockers, Beta2 sympathomimetics, Calcium channel blockers, Calcium salts, Carbamazepine, Cardiac glycosides, Clonidine, Denosumab, Diazoxide, Diuretics, Erythromycin, Estrogens, Fluconazole, Fosaprepitant, Histamine, Hydralazine, Isoniazid, Itraconazole, Ketoconazole, Leflunomide, Leflunomide, Live vaccines, Loop diuretics, Macrolide antibiotics, Methyl salicylate, Methyldopa, Mifamurtide, Mifepristone, Minoxidil, Mitotane, Moxonidine, Natalizumab, Neuromuscular blocking agents, Nitrates, Nitroprusside, NSAIDs, Oral Contraceptives, Pancuronium, Phenindione, Phenobarbital, Phenytoin, Pimecrolimus, Primidone, Quinolones, Rifampin, Rifamycin derivatives, Salicylates, Sipuleucel-T, Sodium benzoate, Sodium phenylbutyrate, Somatropin, Tacrolimus, Thiazides, Vaccines, Vecuronium, Warfarin
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of intravitreal triamcinolone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/10/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
